Clear Search

Showing 1 result for “de la Torre I”.

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus

Dörner T, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222335.

Phase II study results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in patients with SLE.

Read more…